Skip to main content
PMC home page
Springer logoLink to Springer
. 2020 Aug 3;72(5):1271–1287. doi: 10.1007/s43440-020-00151-w

The effects of agomelatine and imipramine on liver cytochrome P450 during chronic mild stress (CMS) in the rat

Anna Haduch 1, Ewa Bromek 1, Marta Rysz 1, Renata Pukło 1, Mariusz Papp 2, Piotr Gruca 2, Magdalena Łasoń 2, Monika Niemczyk 2, Władysława A Daniel 1,✉
PMCID: PMC7550324  PMID: 32748256

Abstract

Background

The aim of our research was to determine the effects of chronic treatment with the atypical antidepressant agomelatine on the expression and activity of liver cytochrome P450 (CYP) in the chronic mild stress (CMS) model of depression, and to compare the results with those obtained for the first-generation antidepressant imipramine.

Methods

Male Wistar rats were subjected to CMS for 7 weeks. Imipramine (10 mg/kg ip/day) or agomelatine (40 mg/kg ip/day) was administered to nonstressed or stressed animals for 5 weeks (weeks 3–7 of CMS). The levels of cytochrome P450 mRNA, protein and activity were measured in the liver.

Results

Agomelatine and imipramine produced different broad-spectrum effects on cytochrome P450. Like imipramine, agomelatine increased the expression/activity of CYP2B and CYP2C6, and decreased the CYP2D activity. Unlike imipramine, agomelatine raised the expression/activity of CYP1A, CYP2A and reduced that of CYP2C11 and CYP3A. CMS modified the effects of antidepressants at transcriptional/posttranscriptional level; however, the enzyme activity in stressed rats remained similar to that in nonstressed animals. CMS alone decreased the CYP2B1 mRNA level and increased that of CYP2C11.

Conclusion

We conclude the following: (1) the effects of agomelatine and imipramine on cytochrome P450 are different and involve both central and peripheral regulatory mechanisms, which implicates the possibility of drug–drug interactions; (2) CMS influences the effects of antidepressants on cytochrome P450 expression, but does not change appreciably their effects on the enzyme activity. This suggests that the rate of antidepressant drug metabolism under CMS is similar to that under normal conditions.

Keywords: Chronic mild stress (CMS), Agomelatine, Imipramine, Liver, Cytochrome P450 expression, Cytochrome P450 activity

Introduction

Cytochrome P450 (CYP) enzymes play an important role in the oxidative metabolism of endogenous substances (e.g. steroids, arachidonic acid, vitamins) and exogenous compounds including drugs. The physiological expression of liver cytochrome P450 is regulated via the hormonal and immune systems [1]. Our earlier studies showed an important role of the brain dopaminergic [2], noradrenergic [3, 4] and serotonergic [5–9] systems in the physiological neuroendocrine regulation of cytochrome P450 expression in the liver. Those central mechanisms may also be involved in the enzyme regulation by psychotropic drugs or stress.

Stress produces changes in the functioning of the nervous, endocrine and immune systems, which may differ depending on its nature, intensity and duration. Stress engages the brain catecholaminergic and other neurotransmitter systems and, in consequence, it affects the endocrine pathways (e.g., stimulation of the HPA axis) and immune responses (i.e. increased production of proinflammatory cytokines) [10–13]. Stress-evoked changes in these systems may affect cytochrome P450 expression and activity and modify the effect of psychotropic drugs on the enzyme. Our recent studies have indicated that chronic mild stress (CMS) affects liver cytochrome P450 and modifies the action of the atypical neuroleptic lurasidone or the antidepressants venlafaxine and escitalopram, on cytochrome P450 in the liver or brain [14, 15].

It seems, therefore, interesting to find out the effects of chronic treatment with the novel antidepressant and antianxiety drug agomelatine [16–19] on liver cytochrome P450 at normal conditions and under CMS, with reference to the model antidepressant imipramine.

Imipramine, a dibenzoazepine derivative, is a noradrenaline and serotonin reuptake inhibitor having also some antagonistic properties at noradrenergic α1, histaminergic H1 and muscarinic acetylcholine M1 receptors [20]. Agomelatine, a naphthalene analogue of melatonin, is known as an antagonist of serotonergic 5-HT2C receptors and agonist of melatonergic MT1 and MT2 receptors, and these two antagonistic/agonistic receptor effects give a synergistic beneficial therapeutic outcome [21–23]. By blocking 5-HT2C receptors located on GABA-ergic interneurons in the brain stem, agomelatine disinhibits dopamine and noradrenaline release in the prefrontal cortex [24], while by stimulating melatonergic receptors in the suprachiasmatic nucleus agomelatine exerts its chronobiotic effect (“resynchronizing” circadian rhythms) [25, 26]. Chronic treatment with agomelatine increases neural plasticity and adult neurogenesis, in particular in the hippocampus [27, 28]. By acting on those serotonergic and melatonergic receptors the antidepressant increases the contents of brain-derived neurotrophic factor [29, 30] and reduces release of glutamate in limbic structures [31, 32]. The synergy of 5-HT2C receptor antagonism and melatonergic receptor agonism is advantageous for the abovementioned pharmacological effects of agomelatine [33–35], as well as for the treatment of depression and anxiety.

Imipramine is known to be metabolized by a few CYP enzymes, i.e. by CYP2D6-catalyzed aromatic hydroxylation as well as CYP1A2-, CYP2C19- and CYP3A4-mediated N-demethylation [36, 37]. At pharmacological concentrations, it affects cytochrome P450 enzymes in the liver via different mechanisms [38–43]. However, the effect of long-term treatment with this drug (5 weeks, mimicking clinical conditions) on cytochrome P450 activity at normal conditions and under stress has not been studied so far.

Interactions between agomelatine and cytochrome P450 are less known. The drug is mainly metabolized by CYP1A2 and to a much lesser extent by CYP2C9 and CYP2C19 via hydroxylation and demethylation to form inactive metabolites. Moreover, CYP1A2 and CYP3A4 contribute to the formation of GSH adducts and hydrazones [44, 45]. Potential effects of agomelatine on cytochrome P450 at pharmacological/therapeutic concentrations are not known; however, it has been mentioned that high oral doses (≥ 125 mg/kg) induce cytochrome P450 in rodents and monkeys [46]. Moreover, clinical trials indicate that the risk of drug-induced hepatotoxicity is greater for agomelatine than for other antidepressants [47, 48], which may be connected with epoxide formation [44]. Both imipramine and agomelatine show antidepressant- and anxiolytic-like activity in animal models of depression or anxiety [49–52]. The aim of our research was to determine the effects of chronic treatment with agomelatine on the expression and activity of liver cytochrome P450 in the CMS model of depression [53] and to compare the results with those obtained for imipramine.

Materials and methods

Animals

All procedures used in this study were in accordance with the 86/609 EEC Directive, and were approved by the Local Bioethics Commission at the Maj Institute of Pharmacology, Polish Academy of Sciences. The experiments were carried out on male Wistar Han rats (Charles River Laboratories, Sulzfeld, Germany), weighing 280–300 g. The animals were singly housed with food and water freely available, and were maintained on a 12-h light/dark cycle (light on at 08.00 h) under conditions of constant temperature (22 ± 2 °C) and humidity (50 ± 5%).

Drugs and chemicals

Imipramine (hydrochloride) was provided by Sigma (St. Louis, MO, USA), agomelatine by Carbosynth (Berkshire, UK). NADP, NADPH, glucose-6-phosphate-dehydrogenase, glucose-6-phosphate, caffeine and its metabolites, bufuralol and its metabolite 1′-hydroxybufuralol and RNA-free water were purchased from Sigma (St. Louis, MO, USA). Testosterone and its metabolites were provided by Steraloids (Newport, KY, USA). Warfarin was donated by Merck (Darmstadt, Germany), while 7-hydroxywarfarin was synthesized at our Institute [24]. The primary mouse monoclonal anti-rat CYP2C6, the rabbit polyclonal anti-rat CYP2C11 and anti-human CYP2D6 antibodies were obtained from Abcam (Cambrige, UK), the rabbit anti-rat CYP3A1 and CYP3A2 antibodies came from Millipore (Temecula, USA). The polyclonal primary rabbit anti-human CYP2A13, the monoclonal mouse anti-rat CYP2B1/2B2 and the polyclonal anti-rat β-actin antibodies were from Santa Cruz Biotechnology (Dallas, TX, USA). The polyclonal primary anti-rat CYP1A1 antibody was from Daiichi Pure Chemicals (Tokyo, Japan). Horseradish peroxidase-labeled secondary antibodies and goat anti-mouse were from Jackson ImmunoResearch (West Grove, PA, USA) and goat anti-rabbit from Vector Laboratories (Burlingame, CA, USA). Rat cDNA-expressed CYP1A1, CYP2B1, CYP2C6, CYP2C11, CYP3A1/23, CYP3A2, human cDNA-expressed CYP2D6 (Supersomes) and pooled human liver microsomes were from Gentest Corp. (Woburn, MA, USA). The chemiluminescence reagents LumiGlo kit came from KPL (Gaithersburg, MD, USA). A mirVana kit, TaqMan assays and the TaqMan Gene Expression Master Mix from Life Technologies (Carlsbad, CA, USA), and a Transcriptor High-Fidelity cDNA synthesis kit from Roche Diagnostics (Indianapolis, IN, USA) were used for RNA isolation and mRNA estimation.

In vivo experiment and preparation of liver microsomes

CMS experiments and sucrose consumption test were performed according to the methods described previously [15, 54]. Briefly, rats were subjected to the CMS procedure for 7 weeks. The weekly stress procedure included two periods of food or water deprivation, 45 degree cage tilt, intermittent illumination, soiled cage (water in sawdust bedding), one period of paired housing, two periods of low-intensity stroboscopic illumination, and three periods of no stress, according to the CMS protocol [54, 55]. All stressors lasted for 10–14 h and were applied individually and incessantly, day and night. After 2 weeks of initial stress, both nonstressed and stressed animals were divided into three subgroups and for the next 5 weeks received once-daily intraperitoneal injections (ip) of vehicle (saline, 1 ml/kg), imipramine (10 mg/kg) or agomelatine (40 mg/kg). The applied doses were optimal to achieve an antidepressant effect in the rat CMS model, as measured by sucrose consumption test [49, 52]. Stress was continued throughout the time of the treatment (5 weeks). After the stress procedure and antidepressant treatment were completed, animals underwent biochemical studies into cytochrome P450 expression and activity in the liver. All animals were killed by decapitation (24 h after the last dose). Their livers were quickly isolated, frozen in dry ice and stored at -80 °C. Liver microsomes were prepared from individual rats by differential centrifugation (11,000×g and 2 × 100,000×g) in a 20 mM Tris/KCl buffer (pH 7.4), including washing with 0.15 M KCl, as described previously [38]. The above procedure deprives microsomes of in vivo administered drugs.

Determination of CYP enzyme activity in the liver

The activities of CYP enzymes were studied at the linear conditions as concerns time, protein and substrate concentration, according to the previously optimized conditions. Incubations were carried out in a medium containing liver microsomes (ca. 1 mg of protein/ml) and NADP or NADPH-generating system as described previously. The activity of CYP1A was determined by measuring the rate of caffeine metabolism (C-8-hydroxylation and 3-N-demethylation) at a substrate concentration of 100 μM and incubation time of 50 min. Caffeine and its metabolites were analyzed by HPLC with UV detection [56]. The activity of CYP2C6 was studied by measuring the rate of warfarin 7-hydroxylation at a substrate concentration of 60 μM and incubation time of 15 min. Warfarin and its metabolite were analyzed by HPLC with fluorescence detection [40]. The activity of CYP2D was estimated by measuring the rate of bufuralol 1′-hydroxylation at a substrate concentration of 10 μM and incubation time of 10 min. Bufuralol and its metabolite were analyzed by HPLC with fluorescence detection [57, 58]. The activities of CYP2A, CYP2B, CYP2C11 and CYP3A were studied by measuring the rate of cytochrome P450 enzyme-specific reactions: the 7α-, 16β-, 2α- and 16α-, and 6β-hydroxylation of testosterone, respectively, at a substrate concentration of 100 μM and incubation time of 15 min, as described previously. Testosterone and its metabolites were analyzed by HPLC with UV detection [41–43].

Analysis of CYP proteins in the liver

The protein levels of CYP1A, CYP2A, CYP2C11, CYP2B, CYP2D, CYP3A1/23 and CYP3A2 in the liver microsomes (10 µg of proteins) of control and antidepressant-treated rats were estimated by Western immunoblot analysis, as previously described [5, 6, 14]. Monoclonal anti-rat CYP2B and CYP2C6, polyclonal anti-rat CYP1A1, CYP2C11, CYP3A1/23 or CYP3A2 antibodies, anti-human CYP2A13 (reacting with rat CYP2A) and CYP2D6 (reacting with rat CYP2D) antibodies, and a secondary antibody (a species-specific horseradish peroxidase-conjugated anti-IgG) were used. Rat cDNA-expressed CYP1A1, CYP2B1, CYP2C6, CYP2C11 (5 µg), CYP3A1/23, CYP3A2 (1 µg) and human cDNA-expressed CYP2D6 (1 µg) or pooled human liver microsomes (20 µg, reacting with anti-human CYP2A13 antibodies) were used as respective standards. The intensity of the bands on a nitrocellulose membrane was quantified with the Luminescent Image Analyzer and the data were normalized to protein loading based on the β-actin levels [5, 6].

Isolation of liver RNA and quantitative real-time polymerase chain reaction (qRT-PCR) measurements

RNA was isolated from the liver, and quantitative real-time PCR was performed as described previously [6]. Briefly, frozen liver tissue was homogenized, and total RNA was extracted using a mirVana isolation kit and then the first-strand cDNA products were generated using a Transcriptor High Fidelity cDNA Synthesis Kit. The expression of the genes encoding the cytochrome P450 enzymes (CYP1A1, CYP1A2, CYP2A1, CYP2A2, CYP2B1, CYP2B2, CYP2C11, CYP2C6, CYP3A1/23, CYP3A2, CYP2D1 and CYP2D2) and the reference genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin were detected by real-time PCR using commercially available TaqMan Gene Expression Master Mix and species-specific TaqMan type probes and primers. The gene names for the tested CYP genes and two reference genes with identification numbers of the TaqMan primers used in the study are as follows: CYP1A1 (Rn01418021_g1), CYP1A2 (Rn00561082_m1), CYP2A1 (Rn04219367_m1), CYP2A2 (Rn00562207_m1), CYP2C6 (Rn03417171_gH), CYP2B1 (Rn01457880_m1), CYP2B2 (Rn02786833_m1), CYP2C11 (Rn01502203_m1), CYP3A1/23 (Rn03062228_m1), CYP3A2 (Rn00756461_m1), CYP2D1 (Rn01775090_mH), CYP2D2 (Rn00562419_m1), GAPDH (Rn01462662_g1) and β-actin (Rn00667869_m1). Real-time PCR runs were performed using the Bio-Rad CFX96 PCR system (Bio-Rad, Hercules, CA, USA) as described previously [6]. The level of the CYP transcripts was normalized to the β-actin expression (β-actin was chosen as a reference gene since its expression was stable compared to that of GAPDH after the applied treatments), and the relative quantification was obtained by a comparative delta–delta Ct method (2-ΔΔCt).

Statistical analysis of data

All data are reported as the means (± S.E.M.). The results of CYP protein levels were analyzed using one-way analysis of variance (ANOVA) followed by the post hoc Duncan’s test. Because of limited area on the electrophoresis gel or nitrocellulose membrane, separate Western blot analyses of CYP proteins for non-stressed and stressed animals were carried out. Thus, the CYP protein levels were tested separately for nonstressed (nonstressed control, imipramine and agomelatine) and stressed (stressed control, imipramine and agomelatine) groups of animals. Statistically significant values of F and p generated in the one-way ANOVA analysis are shown in Table 2. But the results of CYP mRNA levels and activity were analyzed using two-way ANOVA followed by the post hoc Duncan’s test, since in this case nonstressed and stressed groups were tested jointly. Therefore, two factors were taken into account in the two-way ANOVA: factor I (stressed/nonstressed) and factor II (imipramine/agomelatine/saline control). Statistically significant values of F and p derived from the two-way ANOVA analysis of CYP mRNA levels and activity are shown in Tables 1 and 3, respectively. All the p values of Duncan’s test are presented in the figure captions. The results were considered as statistically significant when p < 0.05.

Table 2.

Statistically significant values of F and p derived from the one-way ANOVA carried out to analyze the results of CYP protein levels

CYP Nonstressed
Saline/IMI/AGM		 Stressed
Saline/IMI/AGM
F p F p
1A F2,21 = 14.092 0.0001 F2,21 = 26.075 0.0000
2A F2,15 = 16.442 0.0002 F2,15 = 1.677 0.2202
2B F2,15 = 17.713 0.0001 F2,15 = 60.471 0.0000
2C6 F2,15 = 48.480 0.0000 F2,15 = 50.671 0.0000
2C11 F2,15 = 63.026 0.0000 F2,15 = 38.863 0.0000
2D F2,15 = 0.623 0.5503 F2,15 = 3.938 0.0622
3A1 F2,21 = 42.661 0.0000 F2,20 = 18.703 0.0000
3A2 F2,15 = 35.051 0.0000 F2,15 = 55.456 0.0000
Open in a new tab

The CYP protein levels were tested separately for nonstressed (saline control, imipramine and agomelatine) and stressed (saline control, imipramine and agomelatine) groups of animals. The values of F and p marked in bold indicate statistically significant changes in the CYP protein level within studied factor

Table 1.

Statistically significant values of F and p derived from the two-way analysis of variance (ANOVA) carried out to analyze the results of CYP mRNA levels for: factor I—–stressed/nonstressed, factor II—IMI/AGM/saline control, and for the interaction between factors I and II–stressed/nonstressed × IMI/AGM/saline control

CYP Stressed/nonstressed IMI/AGM/saline Stressed/nonstressed × IMI/AGM/saline
F p F p F p
1A1 F1,36 = 0.081 0.777478 F2,36 = 1.712 0.194960 F2,36 = 4.855 0.013590
1A2 F1,35 = 36.8005 0.070001 F2,35 = 17.1684 0.000006 F2,35 = 14.4333 0.0000027
2A1 F1,38 = 0.58164 0.450380 F2,38 = 9.42655 0.000474 F2,38 = 0.89181 0.418319
2A2 F1,38 = 2.9081 0.096300 F2,38 = 5.4948 0.008015 F2,38 = 3.3756 0.044730
2B1 F1,34 = 19.044 0.000113 F2,34 = 46.665 0.000000 F2,34 = 1.017 0.372560
2B2 F1,30 = 3.8644 0.059000 F2,30 = 22.6668 0.000001 F2,30 = 0.2539 0.777443
2C6 F1,30 = 3.232177 0.082277 F2,30 = 4.060722 0.027497 F2,30 = 5.404912 0.009893
2C11 F1,34 = 3.81696 0.049003 F2,34 = 14.82431 0.000023 F2,34 = 4.35875 0.020646
2D1 F1,36 = 0.620 0.436594 F2,36 = 8.233 0.125700 F2,36 = 0.759 0.476247
2D2 F1,36 = 5.7272 0.022043 F2,36 = 3.4908 0.041151 F2,36 = 2.8598 0.070361
3A1 F1,36 = 5.2605 0.027759 F2,36 = 6.3422 0.0043681 F2,36 = 2.1900 0.126600
3A2 F1,32 = 3.42780 0.073355 F2,32 = 26.968 0.000000 F2,32 = 0.52249 0.598017
Open in a new tab

The values of F and p marked in bold indicate statistically significant changes in the mRNA levels of CYPs within and between studied factors

IMI imipramine, AGM agomelatine

Table 3.

Statistically significant values of F and p derived from the two-way analysis of variance (ANOVA) carried out to analyze the results of CYP activity levels for: factor I—stressed/nonstressed, factor II—IMI/AGM/saline control, and for the interaction between factors I and II—stressed/nonstressed × IMI/AGM/saline control

CYP Stressed/nonstressed IMI/AGM/saline Stressed/nonstressed × IMI/AGM/saline
F p F p F p
1A

F1,54 = 0.1953

F1,54 = 0.1868

0.660323

0.667319

F2,54 = 9.8423

F2,54 = 4.2945

0.000227

0.018585

F2,54 = 0.0487

F2,54 = 0.4035

0.952490

0.669987
2A F1,53 = 0.602 0.441280 F2,53 = 27.298 0.000000 F2,53 = 1.459 0.241631
2B F1,53 = 0.7534 0.389308 F2,53 = 7.4751 0.001381 F2,53 = 0.0056 0.994380
2C6 F1,52 = 1.933 0.170303 F2,52 = 14.051 0.000013 F2,52 = 1.568 0.218204
2C11

F1,50 = 4.6492

F1,45 = 3.0059

0.035904

0.089809

F2,50 = 24.3904

F2,45 = 20.6261

0.000000

0.000000

F2,50 = 0.1450

F2,45 = 0.1266

0.865420

0.881420
2D F1,52 = 0.9777 0.327337 F2,52 = 65.0573 0.000000 F2,52 = 1.2554 0.293456
3A F1,48 = 2.825 0.099311 F2,48 = 10.129 0.000214 F2,48 = 0.954 0.392213
Open in a new tab

The values of F and p marked in bold indicate statistically significant changes in the activity of CYPs within and between studied factors

IMI imipramine, AGM agomelatine

Results

The effect of imipramine and agomelatine on the CYP1A expression and activity in the liver of nonstressed and stressed rats

Chronic mild stress (CMS) did not affect the expression or activity of CYP1A enzymes (Fig. 1a, c, respectively). Imipramine tended to elevate the mRNA levels of both CYP1A1 and CYP1A2 in nonstressed rats, but decreased those levels in stressed animals (Fig. 1a). Thus the expression of CYP1A1/2 genes under antidepressant treatment was significantly lower in stressed animals whereas the protein level of CYP1A gently increased in stressed animals only (Fig. 1b). The activity of CYP1A (measured as the caffeine C-8-hydroxylation and 3-N-demethylation) remained unchanged after imipramine treatment (Fig. 1c), though a tendency to increase was observed in both groups of rats (nonstressed and stressed).

Fig. 1.

Fig. 1

Open in a new tab

The influence of a 5-week treatment with imipramine or agomelatine on the expression and activity of CYP1A in the liver from the chronic mild stress (CMS) model. a The mRNA expression level of CYP1A1 and CYP1A2. Results are expressed as the fold-change in relation to the housekeeping gene β-actin (n = 6–8), the outcome of two-way ANOVA is shown in Table 1; b CYP1A protein level (n = 8), the outcome of one-way ANOVA is shown in Table 2; c CYP1A activity measured as a rate of caffeine 3-N-demethylation (n = 9–10), the outcome of two-way ANOVA is shown in Table 3. Results are shown as the means ± S.E.M. Duncan’s test: statistical significance is shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to the nonstressed control; +p < 0.05, ++p < 0.01, +++p < 0.001 compared to the stressed control; $p < 0.05, $$$p < 0.001 compared to the nonstressed imipramine-treated rats; #p < 0.01 compared to the nonstressed agomelatine-treated rats. The representative CYP1A protein bands of the Western immunoblot analysis are shown in Fig. 8. CON control, IMI imipramine, AGM agomelatine, 1,3,7-TMU 1,3,7-trimethyluric acid

Agomelatine significantly increased the mRNA level of CYP1A2 in nonstressed rats (Fig. 1a), not affecting significantly CYP1A1 mRNA. The CYP1A1/2 mRNA levels remained unchanged in stressed animals under antidepressant treatment, but the CYP1A2 mRNA level was lower compared to nonstressed animals treated with agomelatine. However, the antidepressant increased the CYP1A protein level (Fig. 1b) and activity (Fig. 1c) in both groups of rats.

The effect of antidepressants on the CYP2A expression and activity in the liver of nonstressed and stressed rats

CMS did not exert any effect on the expression or activity of CYP2A enzymes (Fig. 2a, c, respectively). Imipramine did not affect the mRNA level of CYP2A1 or CYP2A2 in nonstressed rats, though gently decreased that of CYP2A2 in stressed animals (Fig. 2a). The CYP2A protein level and activity (testosterone 7α-hydroxylation) remained unchanged after imipramine treatment (Fig. 2b, c, respectively).

Fig. 2.

Fig. 2

Open in a new tab

The influence of a 5-week treatment with imipramine or agomelatine on the expression and activity of CYP2A in the liver from the chronic mild stress (CMS) model. a The mRNA expression level of CYP2A1 and CYP2A2. Results are expressed as the fold-change in relation to the housekeeping gene β-actin (n = 7–8), the outcome of two-way ANOVA is shown in Table 1; b CYP2A protein level (n = 6), the outcome of one-way ANOVA is shown in Table 2; c CYP2A activity measured as a rate of testosterone 7α-hydroxylation (n = 9–10), the outcome of two-way ANOVA is shown in Table 3. Results are shown as the means ± S.E.M. Duncan’s test: statistical significance is shown as *p < 0.05, ***p < 0.001 compared to the nonstressed control; +p < 0.05, ++p < 0.01 compared to the stressed control; $p < 0.05 compared to the nonstressed imipramine-treated rats. The representative CYP2A protein bands of the Western immunoblot analysis are shown in Fig. 8. CON control, IMI imipramine, AGM agomelatine

Agomelatine moderately raised the CYP2A1 and CYP2A2 mRNAs (Fig. 2a) and CYP2A protein level (Fig. 2b) only in nonstressed rats, but significantly increased the activity of CYP2A in both nonstressed and stressed animals (Fig. 2c).

The effect of antidepressants on the CYP2B expression and activity in the liver of nonstressed and stressed rats

CMS decreased the CYP2B1 mRNA level (Fig. 3a) not affecting the CYP2B activity (Fig. 3c). Imipramine strongly increased the CYP2B1 and CYP2B2 mRNA levels (up to fivefold) in nonstressed and stressed rats, and the effect on the CYP2B1 mRNA level was more pronounced in nonstressed group (Fig. 3a). The antidepressant significantly increased the CYP2B protein level (Fig. 3b) and activity (Fig. 3c) measured as the testosterone 16β-hydroxylation rate in both nonstressed and stressed animals.

Fig. 3.

Fig. 3

Open in a new tab

The influence of a 5-week treatment with imipramine or agomelatine on the expression and activity of CYP2B in the liver from the chronic mild stress (CMS) model. a The mRNA expression level of CYP2B1 and CYP2B2. Results are expressed as the fold-change in relation to the housekeeping gene β-actin (n = 6–8), the outcome of two-way ANOVA is shown in Table 1; b CYP2B protein level (n = 6), the outcome of one-way ANOVA is shown in Table 2; c CYP2B activity measured as a rate of testosterone 16β-hydroxylation (n = 9–10), the outcome of two-way ANOVA is shown in Table 3. Results are shown as the means ± S.E.M. Duncan’s: statistical significance is shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to the nonstressed control; +p < 0.05, ++p < 0.01, +++p < 0.001 compared to the stressed control; $$p < 0.01 compared to the nonstressed imipramine-treated rats. The representative CYP2B protein bands of the Western immunoblot analysis are shown in Fig. 8. CON control, IMI imipramine, AGM agomelatine

Agomelatine markedly increased the mRNA level of CYP2B1 up to two-fold and CYP2B2 up to three-fold in nonstressed and stressed rats (Fig. 3a). The CYP2B protein level was enhanced only in nonstressed animals (Fig. 3b). The CYP2B activity was not significantly changed by agomelatine treatment in both groups of rats, though a tendency to increase was observed (Fig. 3c).

The effect of antidepressants on the CYP2C6 expression and activity in the liver of nonstressed and stressed rats

CMS did not influence the expression or activity of CYP2C6 (Fig. 4a, c, respectively). The CYP2C6 mRNA level was distinctly increased (up to twofold) by imipramine in nonstressed rats (Fig. 4a), whereas the antidepressant increased the protein level (Fig. 4b) and activity measured as the warfarin 7-hydroxylation rate (Fig. 4c) in both nonstressed and stressed animals.

Fig. 4.

Fig. 4

Open in a new tab

The influence of a 5-week treatment with imipramine or agomelatine on the expression and activity of CYP2C6 in the liver from the chronic mild stress (CMS) model. a The mRNA expression level of CYP2C6. Results are expressed as the fold-change in relation to the housekeeping gene β-actin (n = 6), the outcome of two-way ANOVA is shown in Table 1; b CYP2C6 protein level (n = 6), the outcome of one-way ANOVA is shown in Table 2; c CYP2C6 activity measured as a rate of warfarin 7-hydroxylation (n = 9–10), the outcome of two-way ANOVA is shown in Table 3. Results are shown as the means ± S.E.M. Duncan’s test: statistical significance is shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to the nonstressed control; +p < 0.05, + + +p < 0.001 compared to the stressed control; $$p < 0.01 compared to the nonstressed imipramine-treated rats. The representative CYP2C6 protein bands of the Western immunoblot analysis are shown in Fig. 8. CON control, IMI imipramine, AGM agomelatine

Agomelatine moderately elevated the CYP2C6 mRNA levels in nonstressed rats (Fig. 4a), but increased the CYP2C6 protein level (Fig. 4b) and activity (Fig. 4c) in both nonstressed and stressed groups of animals.

The effect of antidepressants on the CYP2C11 expression and activity in the liver of nonstressed and stressed rats

CMS moderately increased the CYP2C11 mRNA level in the rat liver (Fig. 5a) and showed such a tendency for the enzyme activity measured as the testosterone 2α- and 16α-hydroxylation rate (Fig. 5c). Imipramine treatment significantly decreased the CYP2C11 mRNA level in stressed animals (Fig. 5a). At the same time the antidepressant increased the protein level (Fig. 5b) and activity (Fig. 5c) of CYP2C11 in both nonstressed and stressed groups of rats.

Fig. 5.

Fig. 5

Open in a new tab

The influence of a 5-week treatment with imipramine or agomelatine on the expression and activity of CYP2C11 in the liver from the chronic mild stress (CMS) model. a The mRNA expression level of CYP2C11. Results are expressed as the fold-change in relation to the housekeeping gene β-actin (n = 6–8), the outcome of two-way ANOVA is shown in Table 1; b CYP2C11 protein level (n = 6), the outcome of one-way ANOVA is shown in Table 2; c CYP2C11 activity measured as a rate of testosterone 2α-hydroxylation (n = 8–10), the outcome of two-way ANOVA is shown in Table 3. Results are shown as the means ± S.E.M. Duncan’s test: statistical significance is shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to the nonstressed control; +p < 0.05, ++p < 0.01, +++p < 0.001 compared to the stressed control. The representative CYP2C11 protein bands of the Western immunoblot analysis are shown in Fig. 8. CON control, IMI imipramine, AGM agomelatine

The CYP2C11 mRNA was reduced a little by agomelatine in nonstressed rats, but distinctly dropped down in stressed animals (Fig. 5a). Accordingly, the enzyme protein (Fig. 5b) and activity (Fig. 5c) were also reduced by agomelatine in both treated groups.

The effect of antidepressants on the CYP2D expression and activity in the liver of nonstressed and stressed rats

CMS had no effect on CYP2D1/2 expression or activity (Fig. 6a, c, respectively). The CYP2D2 mRNA level was slightly decreased (Fig. 6a), while that of CYP2D1 showed such a tendency in imipramine-treated rats under stress. The CYP2D protein level was not changed by imipramine (Fig. 6b). However, the activity of CYP2D (the rate of bufuralol 1′-hydroxylation) was decreased by the antidepressant in both groups of animals (Fig. 6c).

Fig. 6.

Fig. 6

Open in a new tab

The influence of a 5-week treatment with imipramine or agomelatine on the expression and activity of CYP2D in the liver from the chronic mild stress (CMS) model. a The mRNA expression level of CYP2D1 and CYP2D2. Results are expressed as the fold-change in relation to the housekeeping gene β-actin (n = 6–8), the outcome of two-way ANOVA is shown in Table 1; b CYP2D protein level (n = 6), the outcome of one-way ANOVA is shown in Table 2; c CYP2D activity measured as a rate of bufuralol 1′-hydroxylation (n = 9–10), the outcome of two-way ANOVA is shown in Table 3. Duncan’s test (a, b, c): statistical significance is shown as *p < 0.05, ***p < 0.001 compared to the nonstressed control; +p < 0.05, +++p < 0.001 compared to the stressed control; $ p < 0.05 compared to the nonstressed imipramine-treated rats. The representative CYP2D protein bands of the Western immunoblot analysis are shown in Fig. 8. CON control, IMI imipramine, AGM agomelatine

Agomelatine gently enhanced the mRNA level of CYP2D2 in nonstressed animals only (Fig. 6a). The CYP2D protein level was not significantly changed (tended to decrease in stressed rats, Fig. 6b) and the enzyme activity was slightly diminished by agomelatine (Fig. 6c) in nonstressed animals only.

The effect of antidepressants on the CYP3A expression and activity in the liver of nonstressed and stressed rats

CMS did not affect the mRNA level of CYP3A1 and CYP3A2 or the CYP3A activity, measured as the testosterone 6β-hydroxylation rate (Fig. 7a, c, respectively). Imipramine treatment distinctly increased the CYP3A2 mRNA levels in nonstressed and stressed rats (Fig. 7a). The CYP3A1/23 mRNA was significantly increased only in nonstressed group (Fig. 7a), and showed such a tendency in stressed group of animals. The antidepressant augmented the protein level of CYP3A1/23 and CYP3A2 in both nonstressed and stressed groups (Fig. 7b). Interestingly, the activity of CYP3A was not affected by imipramine in nonstressed rats, but it was enhanced in stressed animals (Fig. 7c).

Fig. 7.

Fig. 7

Open in a new tab

The influence of a 5-week treatment with imipramine or agomelatine on the expression and activity of CYP3A in the liver from the chronic mild stress (CMS) model. a The mRNA expression level of CYP3A1/23 and CYP3A2. Results are expressed as the fold-change in relation to the housekeeping gene β-actin (n = 6–8), the outcome of two-way ANOVA is shown in Table 1; b CYP3A1/23 and CYP3A2 protein level (n = 6–8), the outcome of one-way ANOVA is shown in Table 2; c CYP3A activity measured as a rate of testosterone 6β-hydroxylation (n = 8–10), the outcome of two-way ANOVA is shown in Table 3. Duncan’s test: statistical significance is shown as *p < 0.05, **p < 0.01, ***p < 0.001 compared to the nonstressed control; +p < 0.05, ++p < 0.01 compared to the stressed control; #p < 0.05 compared to the nonstressed agomelatine-treated rats. The representative CYP3A1 and CYP3A2 protein bands of the Western immunoblot analysis are shown in Fig. 8. CON control, IMI imipramine, AGM agomelatine

Agomelatine significantly diminished the CYP3A2 mRNA (Fig. 7a) and protein level (Fig. 7b) in both nonstressed and stressed rats. The antidepressant decreased the levels of CYP3A1/23 mRNA (Fig. 7a) and protein (Fig. 7b) in stressed group only. Accordingly, agomelatine significantly decreased the CYP3A activity in nonstressed rats (Fig. 7c), and showed such a tendency in stressed animals.

The representative CYP protein bands in imipramine- or agomelatine-treated rats, obtained as a result of Western blotting, are shown in Fig. 8a (nonstressed rats) and Fig. 8b (stressed rats).

Fig. 8.

Fig. 8

Open in a new tab

The effect of a 5-week treatment with imipramine or agomelatine on the intensity of protein bands of cytochrome P450 enzymes (CYP1A, CYP2A, CYP2B, CYP2C6 CYP2C11, CYP2D and CYP3A) in rat liver microsomes from nonstressed (a) and stressed (b) rats. Microsomal proteins were subjected to the Western immunoblot analysis. cDNA-expressed CYP enzymes were used as standards. The representative CYP protein bands in imipramine- or agomelatine-treated rats are shown. The presented results are typical of four separate rats per group. The mean values ± S.E.M. are shown in Figs. 1b, 2b, 3b, 4b, 5b, 6b and 7b. IMI imipramine, AGM agomelatine, STD standard

Statistically significant values of F and p generated in the one-way ANOVA analysis of CYP protein levels are shown in Table 2. Statistically significant values of F and p derived from the two-way ANOVA analysis of CYP mRNA levels and CYP activity are shown in Tables 1 and 3, respectively.

Discussion

This is the first report showing changes in the cytochrome P450 expression and function under agomelatine treatment. The obtained results indicate that chronic administration of the novel antidepressant drug agomelatine produces broad changes in the cytochrome P450 expression and activity, which are different from those elicited by the classical tricyclic antidepressant imipramine. Moreover, chronic mild stress (CMS) modifies the effects of antidepressants on the expression of cytochrome P450 genes, but its influence on the enzyme activity is far less pronounced (summarized in Table 4).

Table 4.

Summary of the effects of CMS and the antidepressant drugs imipramine and agomelatine on the expression and activity of liver cytochrome P450 enzymes

CYPs 1A1 1A2 2A1 2A2 2B1 2B2 2C6 2C11 2D1 2D2 3A1 3A2
CMS vs nonstressed control Activity – – – – ( ↑) – –
mRNA – – – – ↓ – – ↑ – – – –
Imipramine vs nonstressed control Activity ( ↑) – ↑ ↑ ↑ ↓ –
Protein – – ↑ ↑ ↑ – ↑ ↑
mRNA ( ↑) ( ↑) – – ↑ ↑ ↑ – – – ↑ ↑
CMS + imipramine vs stressed control Activity ( ↑) – ↑ ↑ ↑ ↓ ↑
Protein ↑ – ↑ ↑ ↑ – ↑ ↑
mRNA ↓ ↓ – ↓ ↑ ↑ – ↓ – ↓ ( ↑) ↑
Agomelatine vs nonstressed control Activity ↑ ↑ ( ↑) ↑ ↓ ↓ ↓
Protein ↑ ↑ ↑ ↑ ↓ – – ↓
mRNA – ↑ ↑ ↑ ↑ ↑ ↑ ↓ – ↑ – ↓
CMS + agomelatine vs stressed control Activity ↑ ↑ ( ↑) ↑ ↓ – –
Protein ↑ – – ↑ ↓ ( ↓) ↓ ↓
mRNA – – – – ↑ ↑ – ↓ – – – ↓
Open in a new tab

↑, ↓ increase or decrease, respectively; (↑), (↓) a tendency to increase or decrease, respectively; − no change

Imipramine

The reference antidepressant imipramine at the applied dosage (10 mg/kg ip. once a day for 5 weeks) displayed broad-spectrum effects on cytochrome P450 enzyme complex. Imipramine strongly increased the CYP2B1/2 mRNA levels in nonstressed and stressed rats (in spite of decreased CYP2B1 mRNA by CMS) and moderately enhanced those of CYP3A1/2, which was in line with enhancement of the respective enzyme protein levels (CYP2B, CYP3A1/23 and CYP3A2) in both groups of animals. Accordingly, the activity of CYP2B increased in both groups of animals, and this substantial effect was much more pronounced than that observed previously after a shorter 2-week treatment when only a tendency to increase the CYP2B activity was noticed [42].

However, in spite of the increased expression in both groups, the activity of CYP3A was enhanced by imipramine in stressed rats only, which may be connected with a higher production of imipramine reactive metabolites in nonstressed animals that inactivate the enzyme. The possibility of formation of irreversible CYP-iron(II)-nitrosoalkane complexes by imipramine was demonstrated in vitro [59] and confirmed in vivo [52]. It seems, therefore, that the final effect of imipramine on CYP3A activity depends on a balance between enzyme induction and inhibition.

Similarly, imipramine strongly decreased the activity of CYP2D, not affecting significantly the enzyme expression in both groups of animals, which might be caused by inhibitory action of reactive metabolites, i.e. epoxide intermediates formed during hydroxylation of imipramine, on CYP2D protein activity [60]. The decreased CYP2D activity in rat liver microsomes after in vivo treatment with imipramine was observed already after 1-day exposure to the antidepressant and maintained for 2 weeks [38], which substantiates the above-proposed explanation of the imipramine effect on the enzyme [39].

Imipramine significantly increased the CYP2C6 and CYP2C11 activities and protein levels in both nonstressed and stressed animals. However, the CYP2C6 mRNA was increased only in nonstressed rats, while the CYP2C11 mRNA was surprisingly decreased in stressed animals treated with imipramine (in spite of increased the CYP2C11 mRNA by CMS alone). The above results point to the action of imipramine on CYP2C6 at transcriptional and on CYP2C11 at posttranscriptional level (considering nonstressed rats), and modification of imipramine effects by CMS at transcriptional level. It is theoretically possible that CMS may exert a dual action on cytochrome P450 expression. By increasing corticosterone level, CMS may stimulate CYP gene expression. However, due to its action on the immune system and increased production of pro-inflammatory cytokines, CMS may negatively affect CYP gene expression [61, 62]. The final result depends on the intensity of the two mechanisms and their significance for expression of a particular CYP gene.

Imipramine decreased both CYP1A1 and CYP1A2 mRNA levels in stressed animals, which was not reflected by alterations in the enzyme protein level and activity. It suggests that CMS triggers the inhibitory effect of imipramine on the CYP1A gene transcription followed by posttranscriptional modification.

Generally, it may be assumed that the observed effects of chronic treatment with imipramine on cytochrome P450 expression may be partly due to the inhibitory effect of the parent compound and its main metabolite desipramine on noradrenaline uptake which increases brain noradrenergic neurotransmission and thus stimulates the positive central neuroendocrine regulation of enzyme expression [3]. Moreover, an increased noradrenergic transmission decreases proinflammatory cytokines that negatively regulate most of the investigated CYP isoforms [1, 62–64]. On the other hand, the inhibitory effect of the parent drug imipramine on serotonin reuptake leads to the stimulation of brain serotonergic system and negative regulation of the CYP2C11 expression via neuroendocrine mechanism involving 5-HT1A receptors in the hypothalamic paraventricular nuclei and somatostatin-growth hormone pathway [5, 6, 9]. However, as mentioned elsewhere, the effects of imipramine on cytochrome P450 evoked by the above-described mechanisms may be modified by stress and reactive metabolites of the antidepressant.

Agomelatine

Agomelatine elicited miscellaneous changes in cytochrome P450 expression and activity, which were similar, different or opposite compared to those produced by imipramine. Similarly to imipramine, agomelatine at the applied optimal dosage (40 mg/kg ip, once-daily for 5 weeks) significantly increased the CYP2B1 and CYP2B2 mRNA levels in nonstressed and stressed rats. However, the CYP2B protein level was enhanced only in nonstressed animals, while the enzyme activity tended to increase in both groups. This suggests CMS-induced modification of agomelatine effect at a posttranscriptional or posttranslational level. It was found that an increase in enzyme protein phosphorylation might diminish the CYP2B activity [65] or might predispose the enzyme to degradation [66]. It is conceivable that stress-induced elevation in the concentrations of peripheral catecholamines might affect hepatocyte signaling pathways and the CYP2B protein phosphorylation and, in turn, enzyme protein level and activity in agomelatine-treated rats.

Like imipramine, agomelatine also raised the mRNA and protein level and activity of CYP2C6 in nonstressed rats. This indicates stimulation of CYP2C6 gene transcription by agomelatine, which was then translated into reinforced protein synthesis and reflected by enhanced enzyme activity in nonstressed rats. This effect of agomelatine was affected by stress at transcriptional level, since no significant change in the CYP2C6 mRNA level was observed in stressed animals, though the enzyme protein level and activity were slightly increased in the CMS group.

Unlike imipramine, agomelatine reduced the mRNA and enzyme protein level and activity of CYP2C11 and CYP3A2 in both nonstressed and stressed rats and diminished the CYP3A1/23 mRNA and protein level in stressed animals. The above results indicate negative regulation of CYP2C11 and CYP3A2 expression by the antidepressant at a transcriptional level and suggest modification of CYP3A1/23 expression by CMS in agomelatine-treated rats. The observed negative regulation of the expression of the two CYP2C11 and CYP3A2 genes by agomelatine may be caused by the ability of the antidepressant to block 5-HT2C receptors [21–23]. Our recent study has shown that 5-HT2 receptors in the arcuate nuclei of the hypothalamus are engaged in the positive neuroendocrine regulation of cytochrome P450 (CYP2C11 and CYP3A) by the stimulation of hypothalamic GHRH secretion and pituitary growth hormone (GH) release and an increase in the serum GH concentration [7, 8]. GH is known to be a positive regulator of the expression of the main rat CYP isoforms CYP2C11 and CYP3A, which are engaged in the metabolism of steroids and drugs.

Surprisingly, the mRNA of CYP2D1/2 genes (encoding main liver CYP2D enzymes), which are considered as noninducible in the liver, gently rose under agomelatine treatment, which was not reflected by the amount of CYP2D protein, while the enzyme activity was even slightly decreased in nonstressed rats suggesting some drug-induced enzyme inhibition. The latter might possibly be caused by reactive epoxide-metabolites of agomelatine [44]. Interestingly, repeated administration of methamphetamine increased the CYP2D activity, measured using dextromethorphan as a specific substrate in the isolated perfused rat liver model, which suggested enzyme induction [67].

In contrast to imipramine, agomelatine markedly influenced CYP1A and CYP2A enzymes. Agomelatine significantly increased the CYP1A2 mRNA level in nonstressed rats, but the CYP1A protein level and activity considerably rose in both groups of rats. Agomelatine also raised the mRNA and protein level of CYP2A1/2 in nonstressed rats, while the CYP2A activity was enhanced in both groups of animals. The above-mentioned observations suggests some modification of the antidepressant effect by CMS at a transcriptional (CYP1A2 and CYP2A1/2), a posttranscriptional (CYP1A) or a posttranslational (CYP2A) level. As mentioned before, stress-induced increase in inflammatory cytokines may diminish the expression of CYP genes. Moreover, stress-induced changes in phosphorylation processes can affect cytochrome P450 degradation, catalytic activity, substrate binding/specificity and binding of redox partners [66]. Therefore, further molecular investigations are necessary to reveal the mechanism by which CMS affects the CYP1A and CYP2A expression and activity in agomelatine-treated rats.

Thus chronic agomelatine affects all the investigated cytochromes P450 at the level of CYP gene regulation, expression or enzyme function (activity). Some of its effects were modified by stress (the mRNA or protein level of CYP1A/2A/2B/3A1) and possibly by reactive metabolites of agomelatine (the CYP2D activity).

In summary, agomelatine and imipramine produced different broad-spectrum effects on cytochrome P450 expression and activity, which suggests the involvement of pharmacological mechanisms and formation of reactive metabolites in the enzyme regulation. CMS modified the effects of antidepressants, which might be caused by alterations in the function of the brain nervous system [61], affecting in this way peripheral glucocorticoids, catecholamines and cytokines and, in turn, hepatic signaling pathways [13, 14, 62, 68]. Although CMS affected antidepressant effects on cytochrome P450 expression, the enzyme activity remained similar. The observed inconsistencies between the levels of mRNA, protein and enzyme activities suggest some posttranscriptional modifications. This may happen, e.g., when reactive drug metabolites are formed (which may interact with RNA or enzyme protein) or when cell signaling is altered (e.g., cAMP production), thereby affecting the phosphorylation processes and, in turn, activation of transcription factors or enzyme protein synthesis, function or degradation [39, 65, 66].

Conclusions

We conclude that the following: (1) the investigated antidepressants produce different broad-spectrum effects on cytochrome P450 expression and activity: like imipramine, agomelatine increased the expression/activity of CYP2B and CYP2C6, and decreased the CYP2D activity, but unlike imipramine, agomelatine raised the expression/activity of CYP1A, CYP2A, and reduced that of CYP2C11 and CYP3A, which implicates the possibility of drug–drug interactions during combined treatment; (2) the different effects of antidepressants suggest the involvement of central and peripheral regulatory mechanisms as well as interactions between the enzyme and drug reactive metabolites; (3) CMS influences the effects of antidepressants on cytochrome P450 expression (mRNA, enzyme protein), but does not change appreciably their effects on the enzyme activity. This suggests that the rate of antidepressant drug metabolism under CMS is similar to that under normal conditions.

Further molecular studies need to be carried out to elucidate the mechanisms underlying antidepressant/CMS action on cytochrome P450 expression and activity. Moreover, plasma concentrations of agomelatine after the applied dose should be measured in rats under CMS and compared to those observed in patients upon antidepressant treatment to translate the obtained results on humans.

Author contributions

Participated in research design: WAD, MP. Conducted experiment: AH, EB, MR, RP, PG, MŁ, MN. Performed data analysis: AH, WAD. Wrote or contributed to the writing of the manuscript: WAD, AH.

Funding

This study was financially supported by statutory funds from the Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland.

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Wójcikowski J, Daniel WA. The role of the nervous system in the regulation of liver cytochrome P450. Curr Drug Metab. 2011;12:124–138. doi: 10.2174/138920011795016908. [DOI] [PubMed] [Google Scholar]
  • 2.Wójcikowski J, Daniel WA. The brain dopaminergic system as an important center regulating liver cytochrome P450 in the rat. Expert Opin Drug Metab Toxicol. 2009;5:631–645. doi: 10.1517/17425250902973703. [DOI] [PubMed] [Google Scholar]
  • 3.Sadakierska-Chudy A, Haduch A, Rysz M, Gołembiowska K, Daniel WA. The role of brain noradrenergic system in the regulation of liver cytochrome P450 expression. Biochem Pharmacol. 2013;86:800–807. doi: 10.1016/j.bcp.2013.07.017. [DOI] [PubMed] [Google Scholar]
  • 4.Bromek E, Wójcikowski J, Daniel WA. Involvement of the paraventricular (PVN) and arcuate (ARC) nuclei of the hypothalamus in the central noradrenergic regulation of liver cytochrome P450. Biochem Pharmacol. 2013;86:1614–1620. doi: 10.1016/j.bcp.2013.09.006. [DOI] [PubMed] [Google Scholar]
  • 5.Rysz M, Bromek E, Daniel WA. Activation of brain serotonergic system by repeated intracerebral administration of 5-hydroxytryptophan (5-HTP) decreases the expression and activity of liver cytochrome P450. Biochem Pharmacol. 2016;99:113–122. doi: 10.1016/j.bcp.2015.11.014. [DOI] [PubMed] [Google Scholar]
  • 6.Rysz M, Bromek E, Haduch A, Liskova B, Wójcikowski J, Daniel WA. The reverse role of the hypothalamic paraventricular (PVN) and arcuate (ARC) nuclei in the central serotonergic regulation of the liver cytochrome P450 isoform CYP2C11. Biochem Pharmacol. 2016;112:82–89. doi: 10.1016/j.bcp.2016.04.017. [DOI] [PubMed] [Google Scholar]
  • 7.Bromek E, Rysz M, Haduch A, Daniel WA. Serotonin receptors of 5-HT2 type in the hypothalamic arcuate nuclei positively regulate liver cytochrome P450 via stimulation of the growth hormone-releasing hormone/growth hormone hormonal pathway. Drug Metab Dispos. 2019;47:80–85. doi: 10.1124/dmd.118.083808. [DOI] [PubMed] [Google Scholar]
  • 8.Bromek E, Rysz M, Haduch A, Daniel WA. Stimulation of 5-HT2C serotonin receptor subtype in the hypothalamic arcuate nuclei (ARC) increases the cytochrome P450 activity in the liver. Pharmacol Rep. 2019;71:1210–1212. doi: 10.1016/j.pharep.2019.05.010. [DOI] [PubMed] [Google Scholar]
  • 9.Bromek E, Rysz M, Haduch A, Wójcikowski J, Daniel WA. Activation of 5-HT1A receptors in the hypothalamic paraventricular nuclei negatively regulates cytochrome P450 expression and activity in rat liver. Drug Metab Dispos. 2018;46:786–793. doi: 10.1124/dmd.117.079632. [DOI] [PubMed] [Google Scholar]
  • 10.Konstandi M, Johnson E, Lang MA, Malamas M, Marselos M. Noradrenaline, dopamine, serotonin: different effects of psychological stress on brain biogenic amines in mice and rats. Pharmacol Res. 2000;41:341–346. doi: 10.1006/phrs.1999.0597. [DOI] [PubMed] [Google Scholar]
  • 11.Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463:235–272. doi: 10.1016/s0014-2999(03)01285-8. [DOI] [PubMed] [Google Scholar]
  • 12.Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev. 2009;89:535–606. doi: 10.1152/physrev.00042.2006. [DOI] [PubMed] [Google Scholar]
  • 13.Jiang P, Zhang L, Zhu W, Li H, Dang R, Tang M. Chronic stress causes neuroendocrine-immune disturbances without affecting renal vitamin D metabolism in rats. J Endocrinol Invest. 2014;37:1109–1116. doi: 10.1007/s40618-014-0191-5. [DOI] [PubMed] [Google Scholar]
  • 14.Kot M, Haduch A, Papp M, Daniel WA. The effect of chronic treatment with lurasidone on rat liver cytochrome P450 expression and activity in the chronic mild stress model of depression. Drug Metab Dispos. 2017;45:1336–1344. doi: 10.1124/dmd.117.077826. [DOI] [PubMed] [Google Scholar]
  • 15.Haduch A, Rysz M, Papp M, Daniel WA. The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat. Biochem Pharmacol. 2018;156:398–405. doi: 10.1016/j.bcp.2018.09.005. [DOI] [PubMed] [Google Scholar]
  • 16.Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008;42:1822–1831. doi: 10.1345/aph.1L296. [DOI] [PubMed] [Google Scholar]
  • 17.Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013;28:151–159. doi: 10.1002/hup.2294. [DOI] [PubMed] [Google Scholar]
  • 18.Kennedy SH, Avedisova A, Belaïdi C, Picarel-Blanchot F, de Bodinat C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Eur Neuropsychopharmacol. 2016;26:378–389. doi: 10.1016/j.euroneuro.2015.09.006. [DOI] [PubMed] [Google Scholar]
  • 19.Buoli M, Grassi S, Serati M, Altamura AC. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2017;18:1373–1379. doi: 10.1080/14656566.2017.1359257. [DOI] [PubMed] [Google Scholar]
  • 20.Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol. 1997;17(Suppl 1):2S–18S. doi: 10.1097/00004714-199704001-00002. [DOI] [PubMed] [Google Scholar]
  • 21.Srinivasan V, Zakaria R, Othman Z, Lauterbach EC, Acuña-Castroviejo D. Agomelatine in depressive disorders: its novel mechanisms of action. J Neuropsychiatry Clin Neurosci. 2012;24:290–308. doi: 10.1176/appi.neuropsych.11090216. [DOI] [PubMed] [Google Scholar]
  • 22.Guardiola-Lemaitre B, de Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171:3604–3619. doi: 10.1111/bph.12720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Stahl SM. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr. 2014;19:207–212. doi: 10.1017/S1092852914000248. [DOI] [PubMed] [Google Scholar]
  • 24.Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet J-M, Cussac D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954–964. doi: 10.1124/jpet.103.051797. [DOI] [PubMed] [Google Scholar]
  • 25.Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms. 1998;13:39–51. doi: 10.1177/074873098128999907. [DOI] [PubMed] [Google Scholar]
  • 26.Ying SW, Rusak B, Mocaër E. Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons. Eur J Pharmacol. 1998;342:29–37. doi: 10.1016/s0014-2999(97)01443-x. [DOI] [PubMed] [Google Scholar]
  • 27.Banasr M, Duman RS. Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol Disord Drug Targets. 2007;6:311–320. doi: 10.2174/187152707783220929. [DOI] [PubMed] [Google Scholar]
  • 28.Dagyte G, Trentani A, Postema F, Luiten PG, Den Boer JA, Gabriel C, Mocaër E, Meerlo P, Van der Zee EA. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci Ther. 2010;16:195–207. doi: 10.1111/j.1755-5949.2009.00125.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Soumier A, Banasr M, Lortet S, Masmejean F, Bernard N, Kerkerian-Le-Goff L, Gabriel C, Millan MJ, Mocaer E, Daszuta A. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology. 2009;34:2390–2403. doi: 10.1038/npp.2009.72. [DOI] [PubMed] [Google Scholar]
  • 30.Ladurelle N, Gabriel C, Viggiano A, Mocaër E, Baulieu EE, Bianchi M. Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology. 2012;221:493–509. doi: 10.1007/s00213-011-2597-5. [DOI] [PubMed] [Google Scholar]
  • 31.Reagan LP, Reznikov LR, Evans AN, Gabriel C, Mocaër E, Fadel JR. The Antidepressant agomelatine inhibits stress-mediated changes in amino acid efflux in the rat hippocampus and amygdala. Brain Res. 2012;1466:91–98. doi: 10.1016/j.brainres.2012.05.039. [DOI] [PubMed] [Google Scholar]
  • 32.Milanese M, Tardito D, Musazzi L, Treccani G, Mallei A, Bonifacino T, Gabriel C, Mocaer E, Racagni G, Popoli M, Bonanno G. Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes. BMC Neurosci. 2013;14:75. doi: 10.1186/1471-2202-14-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Molteni R, Calabrese F, Pisoni S, Gabriel C, Mocaer E, Racagni G, Riva MA. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry. 2010;11:148–153. doi: 10.3109/15622970903447659. [DOI] [PubMed] [Google Scholar]
  • 34.Tardito D, Milanese M, Bonifacino T, Musazzi L, Grilli M, Mallei A, Mocaer E, Gabriel-Gracia C, Racagni G, Popoli M, Bonanno G. Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways. BMC Neurosci. 2010;11:68. doi: 10.1186/1471-2202-11-68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology. 2013;38:275–284. doi: 10.1038/npp.2012.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Brøsen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther. 1991;49:609–617. doi: 10.1038/clpt.1991.77. [DOI] [PubMed] [Google Scholar]
  • 37.Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993;43:827–832. [PubMed] [Google Scholar]
  • 38.Daniel WA, Haduch A, Wójcikowski J. Inhibition and possibile induction of rat CYP2D after short- and long-term treatment with antidepressants. J Pharm Pharmacol. 2002;54:1545–1552. doi: 10.1211/002235702162. [DOI] [PubMed] [Google Scholar]
  • 39.Daniel WA. The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol. 2005;1:203–217. doi: 10.1517/17425255.1.2.203. [DOI] [PubMed] [Google Scholar]
  • 40.Daniel WA, Haduch A, Syrek M, Boksa J. Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol. 2006;16:580–587. doi: 10.1016/j.euroneuro.2006.01.004. [DOI] [PubMed] [Google Scholar]
  • 41.Haduch A, Wójcikowski J, Daniel WA. The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A. Eur Neuropsychopharmacol. 2006;16:178–186. doi: 10.1016/j.euroneuro.2005.08.004. [DOI] [PubMed] [Google Scholar]
  • 42.Haduch A, Wójcikowski J, Daniel WA. Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008;60:957–965. [PubMed] [Google Scholar]
  • 43.Wójcikowski J, Haduch A, Daniel WA. Effect of antidepressant drugs on cytochrome P450 2C11 (CYP2C11) in rat liver. Pharmacol Rep. 2013;65:1247–1255. doi: 10.1016/s1734-1140(13)71482-8. [DOI] [PubMed] [Google Scholar]
  • 44.Liu X, Lu YF, Guan X, Zhao M, Wang J, Li F. Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. Biochem Pharmacol. 2016;109:70–82. doi: 10.1016/j.bcp.2016.03.020. [DOI] [PubMed] [Google Scholar]
  • 45.Saiz-Rodríguez M, Ochoa D, Belmonte C, Román M, Vieira de Lara D, Zubiaur P, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33:522–531. doi: 10.1177/0269881119827959. [DOI] [PubMed] [Google Scholar]
  • 46.Howland RH. Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults. Neuropsychiatr Dis Treat. 2009;5:563–576. doi: 10.2147/ndt.s5453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Gahr M, Kratzer W, Fuchs M, Connemann BJ. Safety and tolerability of agomelatine: focus on hepatotoxicity. Curr Drug Metab. 2014;15:694–702. doi: 10.2174/1389200215666140926155041. [DOI] [PubMed] [Google Scholar]
  • 48.Freiesleben SD, Furczyk K. A systematic review of agomelatine-induced liver injury. J Mol Psychiatry. 2015;3:4. doi: 10.1186/s40303-015-0011-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Papp M, Gruca P, Boyer PA, Mocaër E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 2003;28:694–703. doi: 10.1038/sj.npp.1300091. [DOI] [PubMed] [Google Scholar]
  • 50.Papp M, Litwa E, Gruca P, Mocaër E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol. 2006;17:9–18. doi: 10.1097/01.fbp.0000181601.72535.9d. [DOI] [PubMed] [Google Scholar]
  • 51.David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, et al. Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J Pharmacol Exp Ther. 2007;321:237–248. doi: 10.1124/jpet.106.109678. [DOI] [PubMed] [Google Scholar]
  • 52.Rossetti AC, Papp M, Gruca P, Paladini MS, Racagni G, Riva MA, et al. Stress-induced anhedonia is associated with the activation of the inflammatory system in the rat brain: restorative effect of pharmacological intervention. Pharmacol Res. 2016;103:1–12. doi: 10.1016/j.phrs.2015.10.022. [DOI] [PubMed] [Google Scholar]
  • 53.Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology. 1997;134:319–329. doi: 10.1007/s002130050456. [DOI] [PubMed] [Google Scholar]
  • 54.Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural–neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005;52:90–110. doi: 10.1159/000087097. [DOI] [PubMed] [Google Scholar]
  • 55.Papp M. Models of affective illness: chronic mild stress in the rat. Curr Protoc Pharmacol. 2012;5:5–9. doi: 10.1002/0471141755.ph0509s57. [DOI] [PubMed] [Google Scholar]
  • 56.Kot M, Daniel WA. Relative contribution of rat cytochrome P450 isoforms to the metabolism of caffeine: the pathway and concentration dependence. Biochem Pharmacol. 2008;75:1538–1549. doi: 10.1016/j.bcp.2007.12.017. [DOI] [PubMed] [Google Scholar]
  • 57.Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun. 1998;249:838–843. doi: 10.1006/bbrc.1998.9232. [DOI] [PubMed] [Google Scholar]
  • 58.Bromek E, Haduch A, Daniel WA. The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study. Eur J Pharmacol. 2010;626:171–178. doi: 10.1016/j.ejphar.2009.09.062. [DOI] [PubMed] [Google Scholar]
  • 59.Bensoussan C, Delaforge M, Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450–iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol. 1995;49:591–602. doi: 10.1016/0006-2952(94)00477-4. [DOI] [PubMed] [Google Scholar]
  • 60.Masubuchi Y, Igarashi S, Suzuki T, Horie T, Narimatsu S. Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate. J Pharmacol Exp Ther. 1996;279:724–731. [PubMed] [Google Scholar]
  • 61.Willner P. The chronic mild stress (CMS) model of depression: History, evaluation and usage. Neurobiol Stress. 2016;6:78–93. doi: 10.1016/j.ynstr.2016.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Zidek Z, Anzenbacher P, Kmonickova E. Current status and challenges of cytokine pharmacology. Br J Pharmacol. 2009;157:342–361. doi: 10.1111/j.1476-5381.2009.00206.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Morgan ET. Down-regulation of multiple cytochrome P450 gene products by inflammatory mediators in vivo. Independence from the hypothalamo-pituitary axis. Biochem Pharmacol. 1993;45:415–419. doi: 10.1016/0006-2952(93)90078-b. [DOI] [PubMed] [Google Scholar]
  • 64.Kudo S, Kawano K. Role of interleukin-1beta in the modulations of cytochrome P450 and heme metabolism in rat liver. J Interferon Cytokine Res. 1999;19:601–607. doi: 10.1089/107999099313730. [DOI] [PubMed] [Google Scholar]
  • 65.Oesch-Bartlomowicz B, Oesch F. Phosphorylation of xenobiotic-metabolizing cytochromes P450. Anal Bioanal Chem. 2008;392:1085–1092. doi: 10.1007/s00216-008-2315-2. [DOI] [PubMed] [Google Scholar]
  • 66.Aguiar M, Masse R, Gibbs BF. Regulation of cytochrome P450 by posttranslational modification. Drug Metab Rev. 2005;37:379–404. doi: 10.1081/dmr-46136. [DOI] [PubMed] [Google Scholar]
  • 67.Dostalek M, Jurica J, Pistovcakova J, Hanesova M, Tomandl J, Linhart I, Sulcova A. Effect of methamphetamine on cytochrome P450 activity. Xenobiotica. 2007;37:1355–1366. doi: 10.1080/00498250701652877. [DOI] [PubMed] [Google Scholar]
  • 68.Konstandi M. Psychophysiological stress: a significant parameter in drug pharmacokinetics. Expert Opin Drug Metab Toxicol. 2013;9:1317–1334. doi: 10.1517/17425255.2013.816283. [DOI] [PubMed] [Google Scholar]

Articles from Pharmacological Reports are provided here courtesy of Springer

RESOURCES